Introduction {#sec1-1}
============

*Helicobacter* *pylori* (*H. pylori*) has been belonging to humans at least for 58,000 years ([@ref1]). The Italian ice mummy, called 'Otzi', which dates to 5,200 years ago, was affected too ([@ref2]). Therefore, many authors have started considering *H. pylori* as a commensal organism and only an opportunistic pathogen ([@ref3]). Anyway analyzing the gastric microbiota, when *H. pylori* is present, it tends to dominate the microbial gastric community and patients have lower bacterial richness and diversity compared to healthy people ([@ref4]).

The prevalence of *H. pylori* infection is higher in non-industrialized countries, but it varies around the world and depends on numerous factors such as age, ethnicity, geographical and socioeconomic status, bacterial virulence, host characteristics and environmental factors (mainly hygienic conditions). The highest infection rates belong to South Korea (50.8%), Shanghai (71.7%) and South Africa (66.1%), while the lowest are in the USA (7.5%) and Australia (15.5%). The higher prevalence rate in children is in Ethiopia (48% in children aged 2-4 years), in Nigeria (82% in children aged 5-9 years) and in Mexico (43% in children aged 5-9 years); while Canadian children have a prevalence of 7.1% (in 5-18 years children). In Europe the most infected children come from Bulgaria (61.7%) and the least infected from the Netherlands (1.2%) ([@ref5]).

*H. pylori* infection is predominantly acquired in early childhood and person-to-person contact within the same household appears to be a key route for the transmission, mainly the mother-child dyad. Siblings and grandparents too, specially grandmothers, can be a potential origin of the spreading ([@ref6], [@ref7]).

After the colonization of the gastric mucosa, *H. pylori* can cause chronic gastritis (usually asymptomatic, particularly in children), peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma, and gastric adenocarcinoma ([@ref8]). Furthermore *H. pylori* was classified by WHO as a carcinogenic of first class; this means it has ascertained carcinogenicity in humans ([@ref9]). Anyway, luckily, the carcinogenic development is quite rare in developed countries while adult or elderly people especially in low-income countries can be at high risk ([@ref10]).

For these reasons, although many authors around the world have been trying to define and optimize the strategy against *H. pylori* infection in children, there is still not a uniformity of diagnostic and therapeutic approach in pediatrics.

When should we investigate the *H. pylori* infection in children? {#sec1-2}
=================================================================

*H. pylori* infection typically remains undetected at the onset because of its lack of specific symptoms ([@ref11]). Since its discovery, many gastrointestinal and extra-gastrointestinal symptoms have been associated to *H. pylori* infection in children. Hence many children have been often treated simply by a 'test and treat strategy' with the purpose to avoid or reduce the future risk of development of severe complications. Most infected people have no significant symptoms and remain symptoms-free throughout life ([@ref12]).

Approximately 10-20% of *H. pylori* infected people may develop gastric or duodenal ulcers, gastric atrophy, intestinal metaplasia, dysplasia, lymphoma, or gastric adenocarcinoma depending on virulence features of the bacteria, host characteristics and environmental factors ([@ref5]).

We do not have pathognomonic symptoms of *H. pylori* infection in children, but recurrent abdominal pain (RAP), perhaps, has been representing the main symptom for which doctors investigate *H. pylori* infection in pediatric age. A recent study in Iran showed that children with RAP had higher *H. pylori* infection rate than controls, although the difference was not statistically significant ([@ref13]) and a study by Sykora *et al* showed a positive correlation between *H. pylori* infection and functional abdominal pain disorders fulfilling the Rome III criteria ([@ref14]). On the contrary, *H. pylori* infection was identified only in 52% of cases in Brazilian children investigated for chronic non-ulcer dyspepsia ([@ref15]).

*H. pylori* infection can be also associated to several extra-gastrointestinal symptoms, mainly acute idiopathic thrombocytopenic purpura, iron-deficiency anemia, B12 deficiency and allergic diseases ([@ref5]) and, although some studies suggest an association between *H. pylori* infection and short stature ([@ref16]), its role on failure to thrive remains controversial ([@ref10], [@ref17]).

How to investigate {#sec1-3}
==================

The last ESPGAHN/NASPGHAN guidelines recommend diagnosing *H. pylori* infection in children only when symptoms, which can usually vary among vomiting, persistent/recurrent abdominal pain and gastrointestinal bleeding, can justify esophagogastroduodenoscopy with histological examinations because it is important to determine the underlying cause of the symptoms and not solely focus on the presence of *H. pylori* infection ([@ref17]).

Despite this, many non-invasive diagnostic exams are available and well validated even in children.

***Serological testing*** is the most widely available non-invasive method for diagnosing *H. pylori* infection. Moreover serology is the only test that is not affected by local changes in the stomach mainly due to drug therapy (proton-pump-inhibitors (PPIs), antibiotics, Non-Steroidal-Anti-Inflammatory-Drugs (NSAIDs)) that could lead to false-negative results in other tests as Urea Breath Test and stool antigen test. Furthermore serological testing is rapid, cheap, and may help in screening populations or in confirming the presence of *H. pylori* infection in case of equivocal results of the other diagnostic methods. Nevertheless, it cannot be used to distinguish between ongoing or past infections neither to monitor the progress of antimicrobial therapy, nor the eradication. The sensitivity ranges from 76% to 84% and specificity from 79% to 90% ([@ref18]).

*H. pylori* ***stool antigen test*** using monoclonal antibodies detects the antigen of the bacterium and not the antibodies and it is able to diagnose an ongoing infection. Low cost, easy use and sample collection at home have increasingly widespread the use of this method. It has a good sensitivity (about 94.6%) and specificity (about 98.4%), only modestly lower than Urea Breath test ([@ref18]).

***Urea Breath Test*** (UBT) is a widely available test with high sensitivity and specificity (from 90% to 100%) for diagnosing *H. pylori* infection. Moreover, its non-invasiveness, the simplicity of execution and safety make it elective in the suspicion of infection in adulthood, childhood, and in pregnancy. However, the specificity of UBT decreases in young children (\< 6 year old) because it requires active cooperation of the patient to avoid false negative results.

Both stool antigen and UBT must be performed at least 4-6 weeks after either PPIs or antibiotics or NASIDs therapy ([@ref18]).

Another non-invasive approach is the detection of IgG ***antibodies*** anti-*H. pylori* in ***urine*** samples. This might represent a good alternative to blood-based antibody tests and has the major benefit that it can be easily applied in the doctor's office. Being a test based on antibodies title, it presents the same limits as the serological test.

The detection of *H. pylori* in saliva and dental plaque are not still standardized ([@ref19]).

***Molecular methods*** applied to gastric biopsy specimens have provided a valuable alternative for detecting antibiotic resistance. Among them, polymerase chain reaction (PCR) and fluorescence *in situ* hybridization (FISH) are the most preeminent ones. Although they are still unusual methods in clinical practice, they are gathering the medical community confidence ([@ref20]).

There is no single test that can be considered as the gold standard for the diagnosis of *H. pylori* infection. The appropriate test for any specific situation will be influenced by the clinical circumstances, the pretest probability of infection, as well as the availability and costs of the individual diagnostic tests. Non-invasive tests are the most usual methods for routine *H. pylori* detection, but they fail to provide complementary information on the location of *H. pylori* in the stomach, on the histopathological lesions underlying the presence of the bacteria and on the antimicrobial profile of the infecting strain. Because of these limitations, it is generally assumed that invasive tests by upper gastrointestinal endoscopy provide a more complete diagnosis. Culture from gastric biopsies should be performed from 2 different locations (i.e. antrum and body) and put in the same jar, for increasing the sensitivity of antimicrobial susceptibility testing ([@ref17]).

Who to treat {#sec1-4}
============

According to the main international guidelines, the primary indications for treating *H. pylori* infection in children are peptic ulcer disease and first-degree familiarity of patients with gastric cancer. Although the eradication is always recommended specially to avoid long-term complications, in children with RAP or functional abdominal pain the risk of not obtaining the complete resolution of symptoms after eradication or the absence of absolute certainty in achieving eradication should always be critically discussed with parents before starting therapy. For these reasons it is essential to perform upper gastrointestinal endoscopy not to misdiagnosis other possible underlying causes.

Furthermore, *H. pylori* eradication seems related to an increase of gastroesophageal reflux disease and allergic diseases. Iron deficiency anemia and idiopathic thrombocytopenic purpura represent the only extra-intestinal diseases where the cause-effect relationship with *H. pylori* infection was demonstrated ([@ref17].)

How to treat {#sec1-5}
============

A "test and treat strategy" is no longer recommended in children ([@ref17]).

Although many efforts have been made in obtaining eradication, several difficulties remain to be overcome. For many years the standard triple therapy (PPIs + amoxicillin + clarithromycin or metronidazole) has been the first-line therapy recommended by the international guidelines for the eradication of *H. pylori* infection. During the last years, the widespread use/abuse of antibiotics, particularly for respiratory tract infections, has led to the emergence of increasing resistance of *H. pylori* infection to common antibiotics, mainly to clarithromycin. A recent study showed an evident increase of clarithromycin resistance, though with no statistical significance, while metronidazole resistance has been reducing in children in our geographical area during the last 13 years. Furthermore, ampicillin resistance has been confirmed to be very rare ([@ref21]).

Unlike more common pathogens, which can usually be managed with a wide variety of treatments, *H. pylori* is only sensitive to a few drugs. Moreover, the widespread use (and, sometimes, abuse) of antibiotics in children to treat common infections has led to a reduction in antibiotics efficacy against this bacterium. The situation is exacerbated by the fact that *H. pylori* itself generates pharmacological resistances that differ depending on the geographic area and compromise successive second and third-line therapies ([@ref22]).

For achieving a successful eradication rate three strategic points should be considered:

a.  The eradication rate by geographic area.

b.  The systematic use of susceptibility testing.

c.  Treatment compliance higher than 90% ([@ref23]).

*H. pylori* antibiotic resistance varies among countries and among areas within the same country. It depends on the frequency of the antibiotics used for treating other infections, especially those of the respiratory system ([@ref5], [@ref21]).

The more recent pediatric international guidelines recommend setting up the eradication therapy based on susceptibility testing. Moreover, before starting an eradication therapy, doctors should emphasize the importance of a strict adherence to therapy ([@ref17]).

Treatment choices if antibiotic susceptibility testing is available {#sec2-1}
-------------------------------------------------------------------

Standard triple therapy (amoxicillin + clarithromycin or metronidazole) or sequential therapy are good options ([Table 1](#T1){ref-type="table"}). All drugs are administered twice a day. In case of failure, bismuth-quadruple therapy (when bismuth is available), concomitant therapy, triple therapy or sequential therapy with high dosage amoxicillin can be chosen as second choices. Triple therapy with amoxicillin at high dosage (75 mg/kg/day) can increase the eradication rate associating between clarithromycin or metronidazole the one that had not been used previously in the first-line choice ([@ref17]). Even sequential therapy with high dosage of amoxicillin, if standard triple therapy was used as first-line, may represent a good second-choice, as we can benefit of the amoxicillin increase associated with the ability of sequential regimen to overcome antibiotic resistance ([table 2](#T2){ref-type="table"}) ([@ref24], [@ref25]).

###### 

First-line therapy if antimicrobial susceptibility is available (PPIs proton pump inhibitors, CLA: clarithromycin, MET: metronidazole). All drugs are administered two times a day

  -------------------------------------------------------------------- ------------------------------ ------------
  Standard Triple Therapy with CLA susceptibility                      PPIs 1-2 mg/kg/day\            10-14 days
                                                                       amoxicillin 50 mg/kg/day\      
                                                                       clarithromycin 20 mg/kg/day    

  Standard Triple Therapy with CLA resistance and MET susceptibility   PPIs 1-2 mg/kg/day\            10-14 days
                                                                       amoxicillin 50 mg/kg/day\      
                                                                       metronidazole 20 mg/kg/day     

  Sequential Therapy                                                   PPIs 1-2 mg/kg/day\            5 days
                                                                       amoxicillin 50 mg/kg/day\      
                                                                       metronidazole 20 mg/kg/day     

                                                                       \+\                            5 days
                                                                       PPIs 1-2 mg/kg/day\            
                                                                       clarithromycin 20 mg/kg/day\   
                                                                       tinidazole 20 mg/kg/day        
  -------------------------------------------------------------------- ------------------------------ ------------

###### 

Second-line therapy by using high dose of amoxicillin in empirical treatment (PPIs proton pump inhibitors, CLA: clarithromycin, MET: metronidazole). All drugs are administered two times a day

  ----------------------------------------------------------------------- ------------------------------ ------------
  Standard Triple Therapy if MET susceptibility and CLA used previously   PPIs 1-2 mg/kg/day\            10-14 days
                                                                          amoxicillin 75 mg/kg/day\      
                                                                          metronidazole 20 mg/kg/day     

  Sequential Therapy if Standard Triple Therapy used previously           PPIs 1-2 mg/kg/day\            5 days
                                                                          amoxicillin 75 mg/kg/day\      
                                                                          metronidazole 20 mg/kg/day     

                                                                          \+\                            5 days
                                                                          PPIs 1-2 mg/kg/day\            
                                                                          clarithromycin 20 mg/kg/day\   
                                                                          tinidazole 20 mg/kg/day        
  ----------------------------------------------------------------------- ------------------------------ ------------

Therapeutic options in empirical treatment {#sec2-2}
------------------------------------------

Standard triple therapy for 10-14 days or sequential therapy for 10 days are equivalent as first-line therapy, remembering that the use of clarithromycin is recommended if its resistance does not exceed 15% in the considered geographic area (see [Table 3](#T3){ref-type="table"}). All drugs are administered twice a day. ([@ref17]) Then, in case of failure, the second-line therapy should be chosen based on antibiotic susceptibility testing.

###### 

First-line therapy in empirical treatment based on local CLA resistance rate (PPIs proton pump inhibitors; CLA: clarithromycin). All drugs are administered two times a day

  ------------------------------------------------------------- ------------------------------ ------------
  Standard Triple Therapy if local CLA resistance rate \<15%    PPIs 1-2 mg/kg/day\            10-14 days
                                                                amoxicillin 50 mg/kg/day\      
                                                                clarithromycin 20 mg/kg/day    

  Standard Triple Therapy if local CLA resistance rate \> 15%   PPIs 1-2 mg/kg/day\            10-14 days
                                                                amoxicillin 50 mg/kg/day\      
                                                                metronidazole 20 mg/kg/day     

  Sequential Therapy                                            PPIs 1-2 mg/kg/day\            5 days
                                                                amoxicillin 50 mg/kg/day\      
                                                                metronidazole 20 mg/kg/day     

                                                                \+\                            5 days
                                                                PPIs 1-2 mg/kg/day\            
                                                                clarithromycin 20 mg/kg/day\   
                                                                tinidazole 20 mg/kg/day        
  ------------------------------------------------------------- ------------------------------ ------------

Otherwise, sequential therapy may be an option even in children with clarithromycin and metronidazole resistance with a good eradication rate, as showed in a recent study ([@ref24]). Standard triple therapy or sequential therapy with amoxicillin at high dosage (75 mg/kg/day) is another valid alternative in case of antimicrobial resistance or in second-line treatment ([table 2](#T2){ref-type="table"}).

Eradication monitoring {#sec2-3}
----------------------

The success of eradication therapy should be monitored 4 to 8 weeks after the end of antibiotic therapy and 2 weeks after stopping PPIs or 4 weeks after stopping antibiotics and NSAIDs by using either fecal antigen or UBT.

Probiotic use seems to be beneficial in *H. pylori* eradication in children ([@ref23]). A mixture of probiotics can also be useful in improving side effects due to antibiotics in adult-affected patients. ([@ref26]).

However, further studies are needed to identify the optimal dose and probiotic combination.

Discussion {#sec1-6}
==========

*H. pylori* infection in children often has *pauci*-or asymptomatic clinic presentation.

The recent pediatric international guidelines recommend investigating *H. pylori* only by using upper gastrointestinal endoscopy because it is important to determine the cause underlying symptoms and not merely focus on *H. pylori* infection. Researchers stress the concept that "test and treat strategy" should no longer be recommended in children. During esophagogastroduodenoscopy, additional biopsy specimens for rapid urease test and culture with susceptibility testing are recommended, but if *H. pylori* infection is an incidental finding during endoscopy, eradication therapy may be considered following careful discussion with parents ([@ref17]).

In children with iron deficiency anemia and idiopathic thrombocytopenic purpura, *H. pylori* infection should be investigated and if positive, it should be treated after other causes have been excluded. Eradication therapy in persistent or functional abdominal pain is not expected to systematically improve symptoms in children ([@ref17]).

Because the best results of *H. pylori* eradication are obtained after the first treatment, subsequent therapies using the same antibiotics should be avoided. The effectiveness of the eradication treatments depends on the sensitivity of *H. pylori* strains, the duration of the therapy and patients' compliance. Nowadays, it is essential to tailor eradication therapy based on the antibiotic susceptibility of *H. pylori* strains specific for the considered geographic area.

Hence, clarithromycin should not be used in empirical treatment of *H. pylori* infection in children if its local resistance rate is higher than 15%. Otherwise its use should be limited only to children with known antimicrobial susceptibility ([@ref21]).

Treatment failure increases the percentage of second-line and third-line therapies, raising the costs of treatments and the number of patients who undergoing numerous antibiotic treatments. So, while choosing between two therapies, it is illogical and unethical to advise using the one with the lower eradication rate as the initial therapy. Considering the restrict choice of antibiotic in children affected by *H. pylori* infection, sequential therapy could be a good treatment option even in case of antimicrobial resistance ([@ref24]). Equally, increasing the dose of amoxicillin could represent a good alternative option in presence of antibiotic resistance.

Therefore, the best eradication therapy of *H. pylori* infection should be based on individual antimicrobial susceptibility. With regards to this, molecular methods from biopsies (real-time PCR and FISH) have become one of the most promising techniques, even preferable to culture by gastric specimens ([@ref20]).

Alternatively, if antimicrobial susceptibility tests are not available, empirical therapy based on local antibiotic resistance still remains the best therapeutic option ([@ref27]).

Finally, since all antibiotic therapies generate unpleasant (but usually not serious) side effects, we believe that the combination with probiotics helps the patient withstand therapy which may easily result in unpleasant ailments (especially of the gastrointestinal tract) ([@ref26]).
